Mr. Max Schwartz reports

ORGANIGRAM TO REPORT FIRST QUARTER FISCAL 2026 RESULTS ON FEBRUARY 10, 2026

Organigram Global Inc. will release earnings results for its first quarter fiscal 2026 ended Dec. 31, 2025, on Tuesday, Feb. 10, 2026, prior to market open.

The company will host a conference call to discuss its results with details as follows:

Date:  Tuesday, Feb. 10, 2026

Time:  8 a.m. Eastern Time

To ensure you are connected for the full call, the company suggests registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through e-mail, including dial-in details and unique conference call codes for entry. Registration is open through the live call.

Participants will receive their details via e-mail.

A replay of the webcast will be available within 24 hours after the conclusion of the call at the Organigram website and will be archived for a period of 90 days following the call.

About Organigram Global Inc.

Organigram Global is a Nasdaq Global Select Market- and Toronto Stock Exchange-listed company whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator and processor. Through its acquisition of Collective Project Ltd., Organigram Global participates in the United States and Canadian cannabinoid beverages markets.

Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, Shred, Monjour, Tremblant, Collective Project, Trailblazer, Boxhot and Debunk. Organigram operates facilities in Moncton, N.B., and Lac Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities and is optimized for formulation refinement, postprocessing of minor cannabinoids, and infused preroll production. The facility in London will be optimized for labelling, packaging and national fulfilment. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.

We seek Safe Harbor.